NagpalSNaSRathnachalamR. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev2005; 26: 662–687.
2.
AscherioAMungerKLLünemannJD. The initiation and prevention of multiple sclerosis. Nat Rev Neurol2012; 8: 602–612.
3.
SundqvistEBäärnhielmMAlfredssonL. Confirmation of association between multiple sclerosis and CYP27B1. Eur J Hum Genet2010; 18: 1349–1352.
4.
HewinsonM. An update on vitamin D and human immunity. Clin Endocrinol (Oxf)2012; 76: 315–325.
5.
SmoldersJMenheerePKesselsA. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler2008; 14: 1–5.
6.
SimpsonSTaylorBBlizzardL. Higher 25-hydroxyvitamin D is associated with lower relapse risk in MS. Ann Neurol2010; 68: 193–203.
7.
RuniaTFHopWCde RijkeYB. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology2012; 79: 261–266.
8.
Pierrot-DeseillignyCRivaud-PéchouxSClersonP. Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Ther Adv Neurol Disord2012; 5: 187–198.
9.
MowryEMKruppLBMilazzoM. Vitamin D status is associated with relapse rate in pediatric onset multiple sclerosis. Ann Neurol2010; 67: 618–624.
10.
Van der MeiIAPonsonbyALDwyerT. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol2007; 254: 581–590.
11.
BrannonPMYetleyEABaileyRL. Overview of the conference “Vitamin D and health in the 21st century: An update”Am J Clin Nutr2008; 88: 483S–490S.
12.
GoldbergPFlemingMCPicardEH. Multiple sclerosis: Decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses1986; 21: 193–200.
13.
KampmanMTSteffensenLHMellgrenSI. Effect of vitamin D3 supplementation on relapses, disease progression and measures of function in persons with multiple sclerosis: Exploratory outcomes from a double-blind randomised controlled trial. Mult Scler2012; 18: 1144–1151.
14.
BurtonJMKimballSViethR. A phase I/II dose escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010; 74: 1852–1859.
15.
ShaygannejadVJanghorbaniMAshtariF. Effects of adjunct low-dose vitamin D on relapsing–remitting multiple sclerosis progression: Preliminary findings of a randomized placebo-controlled study. Mult Scler Int2012: 2012: 452–541.
16.
SteinMSLiuYGrayOM. A randomized trial of high-dose vitamin D2 in relapsing–remitting multiple sclerosis. Neurology2011; 77: 1611–1618.
17.
Soilu-HänninenMAivoJLindströmBM. A randomised, double blind, placebo controlled trial with vitamin D3 as an add-on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry2012; 83: 565–571.
18.
MosayebiGGhazaviAGhasamiK. Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest2011; 40: 627–639.
19.
MarcusJFShalevSMHarrisCA. Severe hypercalcemia following vitamin D supplementation in a patient with multiple sclerosis: A note of caution. Arch Neurol2012; 60: 129–132.
